PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
58 hedge funds and large institutions have $77.3M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
58
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$669K | |
| 2 | +$541K | |
| 3 | +$494K | |
| 4 |
Goldman Sachs
New York
|
+$458K |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$440K |
Top Sellers
| 1 | -$11.2M | |
| 2 | -$1.85M | |
| 3 | -$1.41M | |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.15M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$893K |